<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567372</url>
  </required_header>
  <id_info>
    <org_study_id>00922</org_study_id>
    <nct_id>NCT00567372</nct_id>
  </id_info>
  <brief_title>POSTERIOR SUB-TENON'S Avastin</brief_title>
  <official_title>POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>macular volume</measure>
    <time_frame>baseline, 3,6 and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>macular thickness</measure>
    <time_frame>baseline,3,6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best corrected visual acuity</measure>
    <time_frame>baseline, 3,6 and 12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Diffuse Diabetic Macular Edema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab (Sub-tenon´s injection)</intervention_name>
    <description>a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with diffuse diabetic macular edema non-proliferative diabetic retinopathy Maculat
        thickness ≥250 μ BCVA ≥ 20/400 Without any treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Vera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adai Pérez-Montesinos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Vera-Rodriguez, MD</last_name>
    <phone>525510841400</phone>
    <phone_ext>1171</phone_ext>
    <email>retinamex@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en Mexico</name>
      <address>
        <city>Mexico DF</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoko Burgoa, Lic</last_name>
      <phone>525514841400</phone>
      <phone_ext>1171</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>December 5, 2008</last_update_submitted>
  <last_update_submitted_qc>December 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sandra Vera-Rodriguez</name_title>
    <organization>Asociación para Evitar la Ceguera en Mexico IAP</organization>
  </responsible_party>
  <keyword>Diffuse diabetic macular edema</keyword>
  <keyword>sub-tenon</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

